<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02164812</url>
  </required_header>
  <id_info>
    <org_study_id>AI266-959</org_study_id>
    <nct_id>NCT02164812</nct_id>
  </id_info>
  <brief_title>Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects</brief_title>
  <official_title>A Study to Determine the Concentration-Electrocardiographic Effects of Efavirenz in Healthy Subjects Enriched for CYP2B6 Polymorphisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether multiple doses of Efavirenz has an effect&#xD;
      on the QTc interval (corrected by Fridericia) in CYP2B6 *1/*6 and *6/*6 healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CYP = Cytochrome p-450&#xD;
&#xD;
      Primary Purpose: Other: This is a Phase 1 clinical pharmacology thorough QT study being&#xD;
      conducted as a post marketing requirement&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference from placebo of Efavirenz (EFV) in change from period-specific baseline in the QT interval corrected for heart rate (HR) via Fridericia's method (QTcF) at postdose extraction times (ΔΔQTcF)</measure>
    <time_frame>Days 1, 2, 5, 6, 19 and 20</time_frame>
    <description>QTcF = QT corrected for Fridericia's formula</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference from placebo of EFV in change from period-specific baseline in other ECG parameters: HR, PR, QRS, and uncorrected QT following 14 days of dosing</measure>
    <time_frame>Days 1, 5 and 19</time_frame>
    <description>ECG = Electrocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference from placebo of Moxifloxacin in change from period-specific baseline in QTcF (ΔΔQTcF) following a single dose</measure>
    <time_frame>Days 1, 5 and 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percent of subjects having a maximum QTcF, HR, PR, and QRS outside of pre-specified categories and those having a maximum ΔQTcF outside of pre-specified categories</measure>
    <time_frame>Days 1, 5 and 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of EFV</measure>
    <time_frame>Days 1, 2, 19 and 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of EFV</measure>
    <time_frame>Days 1, 2, 19 and 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration 24 h after a dose (C24) of EFV</measure>
    <time_frame>Days 1, 2, 19 and 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve in one dosing interval (AUC(TAU)) of EFV</measure>
    <time_frame>Days 1, 2, 19 and 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on incidence of AEs, SAEs, AEs leading to discontinuation, marked laboratory abnormalities, findings on 12-lead safety ECG measurements and physical examinations, and abnormalities in vital sign measurements exceeding pre-defined thresholds</measure>
    <time_frame>Up to 30 days after discontinuation of dose (approximately 52 days)</time_frame>
    <description>Serious AE (SAE)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>HIV/AIDS</condition>
  <arm_group>
    <arm_group_label>Moxifloxacin, Placebo, Efavirenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxifloxacin, Placebo, Efavirenz single dose as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>Moxifloxacin, Placebo, Efavirenz</arm_group_label>
    <other_name>Avelox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Moxifloxacin, Placebo, Efavirenz</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Efavirenz</intervention_name>
    <arm_group_label>Moxifloxacin, Placebo, Efavirenz</arm_group_label>
    <other_name>Sustiva®</other_name>
    <other_name>BMS-561525</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit&#xD;
        www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy volunteers, ages 18 to 49 years old&#xD;
&#xD;
          -  BMI 18 to 32 kg/m2&#xD;
&#xD;
          -  Women must not be pregnant or breastfeeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A personal history of clinically relevant cardiac disease, symptomatic or asymptomatic&#xD;
             arrhythmias, presyncope or syncopal episodes, or additional risk factors for torsades&#xD;
             de pointes (eg, heart failure)&#xD;
&#xD;
          -  History of hypokalemia, personal history or family history of prolonged QT interval,&#xD;
             or family history of sudden cardiac death at a young age&#xD;
&#xD;
          -  Any of the following on 12-lead electrocardiogram (ECG) prior to study drug&#xD;
             administration: PR ≥210 msec, QRS ≥120 msec, QT ≥500 msec, QTcF ≥450 msec, HR &lt;45 bpm&#xD;
&#xD;
          -  Second or third degree heart block prior to study drug&#xD;
&#xD;
          -  Positive urine screen for drugs of abuse&#xD;
&#xD;
          -  Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, or Human&#xD;
             Immunodeficiency Virus (HIV)-1, -2 antibody&#xD;
&#xD;
          -  Any of the following lab results outside of the ranges specified below prior to&#xD;
             dosing: Alanine aminotransferase (ALT) &gt;upper limit of normal (ULN), aspartate&#xD;
             aminotransferase (AST) &gt;ULN, Total bilirubin &gt;ULN, Direct bilirubin &gt;ULN, Creatinine&#xD;
             &gt;ULN, Serum potassium &lt;lower limit of normal (LLN), Serum magnesium &lt;LLN&#xD;
&#xD;
          -  History of allergy to Moxifloxacin, Efavirenz or related compounds&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International - Baltimore Epcu</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <verification_date>September 2015</verification_date>
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>June 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2014</study_first_posted>
  <last_update_submitted>September 3, 2015</last_update_submitted>
  <last_update_submitted_qc>September 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

